Switching to Aflibercept in Diabetic Macular Edema Not Responding to Ranibizumab and/or Intravitreal Dexamethasone Implant

Table 4

Subgroup analysis according to CRT < 300 or ≥300 μm at M6.

Final CRT (M6)
	CRT < 300 microns (group 1)	CRT > 300 microns (group 2)	value^a (comparison between groups 1 and 2)
Number of eyes	15	10
Mean letter score at baseline prior to any injection (SD)	50.7 (17.3)	55.7 (15.9)	0.48
Mean letter score preswitch (SD)	55.9 (20.4)	59 (19.1)	0.7
Mean letter score postswitch M3 (SD)	67 (14)	63.4 (20.1)	1
Mean letter score postswitch M6 (SD)	67 (14.8)	62.2 (16.3)	0.45
Mean VA change from preswitch (SD)	11.1 (16.2)	3.2 (12.5)	0.2
F	7.38	0.96
value (ANOVA test)	0.003	0.4
value^b (comparison between VA preswitch and M6 within each group)	0.02	0.44

ANOVA test was performed to assess significance between VA at baseline, preswitch, M3, and M6 after switch to aflibercept within each group. ^a values were obtained after an unpaired nonparametric Mann–Whitney test between groups 1 and 2 at each time point. ^b values were obtained after a paired nonparametric Wilcoxon test between preswitch VA and VA at M6. VA: visual acuity. <0.05 and <0.01.